Evidence map›Paper›PMID 36839864›Full record

ArticlePharmaceutics2023

Mechanisms of a

Komal Umashankar Rao, Ping Li, Charlotte Welinder, Erik Tenland, Pontus Gourdon, Erik Sturegård, James C S Ho, Gabriela Godaly

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Peptide-Based Strategies AgainstPharmaceuticals (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Komal Umashankar RaoDepartment of Microbiology, Immunology and Glycobiology, Institution of Laboratory Medicine, Lund University, SE-22362 Lund, Sweden.
Ping LiDepartment of Experimental Medical Science, Lund University, SE-22362 Lund, Sweden.
Charlotte WelinderSwedish National Infrastructure for Biological Mass Spectrometry, Lund University, SE-22362 Lund, Sweden.ORCID 0000-0001-9626-0576
Erik TenlandDepartment of Microbiology, Immunology and Glycobiology, Institution of Laboratory Medicine, Lund University, SE-22362 Lund, Sweden.
Pontus GourdonDepartment of Experimental Medical Science, Lund University, SE-22362 Lund, Sweden.
Erik SturegårdDepartment of Clinical Microbiology, Institution of Translational Medicine, Lund University, SE-21428 Malmö, Sweden.
James C S HoSingapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singapore 637553, Singapore.ORCID 0000-0002-6131-1297
Gabriela GodalyDepartment of Microbiology, Immunology and Glycobiology, Institution of Laboratory Medicine, Lund University, SE-22362 Lund, Sweden.ORCID 0000-0002-3467-1350
Lund University · SENanyang Technological University · SGUniversity of Copenhagen · DK

Funding

Alfred Österlund Foundation No numberRoyal Physiographic Society of Lund No numberSwedish Heart-Lung Foundation 2021057422Swedish Research Council No number
6 · The paper itself

Abstract

Multidrug-resistant tuberculosis (MDR) continues to pose a threat to public health. Previously, we identified a cationic host defense peptide with activity against

Indexed as

antimicrobial peptidesmechanisms of actionMycobacterium tuberculosistreatment

Identifiers

PMID36839864
PMCPMC9958537
OpenAlexW4319442458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.